Skip to content
Companies

Primary Bioscience

Nanopore protein sequencing for multi-cancer screening

Raised to date

$1.3M

of $1.8M offered across 1 Form D filing

Still open
$500K
Investors
3
Last filed
Jun 23, 2026

About

Primary Bioscience is a Seattle-based life science company developing a single-molecule protein sequencing device for comprehensive, multi-biomarker screening. The instrument uses nanopore-based sensing reengineered from DNA sequencing to read proteins directly, without antibodies or affinity reagents. The company aims to sequence every protein in a sample, including hard-to-detect variations such as single-residue substitutions, splice variants and post-translational truncations. It is positioning the platform both as a multi-cancer early detection tool and as a proteomics research instrument.

A nanopore-native, single-molecule, antibody-free architecture that sequences proteins de novo rather than measuring a predefined panel, unlike affinity-based immunoassays; the company builds the device itself as a platform rather than shipping a single point-solution diagnostic.

Funding

  • EquityFiled Jun 23, 2026Form D/A
    $1.3M/ $1.8M

Product

Single-molecule protein sequencing device

Life science instrument / proteomics platform

A nanopore-based instrument that sequences individual protein molecules to read every protein in a biological sample, forming the basis of a comprehensive proteomics platform.

  • Nanopore-based single-molecule sensing adapted from DNA sequencing to the 20-amino-acid protein alphabet
  • Antibody-free and affinity-reagent-free detection
  • Unbiased sequencing of every protein in a sample

Built for

Cancer early-detection programs and proteomics researchers in drug discovery and human health

People on file